[1]杨思贤,慕奕彤,牛福玉.粪便S100A12，钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析[J].现代检验医学杂志,2022,37(03):172-176.[doi:10.3969/j.issn.1671-7414.2022.03.036]
　YANG Si-xian,MU Yi-tong,NIU Fu-yu.Evaluation Value of Stool S100A12, Fecal Calprotectin and Lactoferrin for Disease Activity and Mucosal Healing in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2022,37(03):172-176.[doi:10.3969/j.issn.1671-7414.2022.03.036]
点击复制

粪便S100A12，钙卫蛋白和乳铁蛋白对溃疡性结肠炎患者疾病活动度和黏膜愈合评估价值分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
172-176
栏目:
检验与临床
出版日期:
2022-05-15

文章信息/Info

Title:
Evaluation Value of Stool S100A12, Fecal Calprotectin and Lactoferrin for Disease Activity and Mucosal Healing in Patients with Ulcerative Colitis
文章编号:
1671-7414（2022）03-172-05
作者:
杨思贤; 慕奕彤; 牛福玉
（营口市中心医院消化内科，辽宁营口 115003）
Author(s):
YANG Si-xian;  MU Yi-tong;  NIU Fu-yu
(Department of Gastroenterology, Yingkou Central Hospital, Liaoning Yingkou 115003,China)
关键词:
溃疡性结肠炎; S100A12; 钙卫蛋白; 乳铁蛋白
分类号:
R574.62；R446.13
DOI:
10.3969/j.issn.1671-7414.2022.03.036
文献标志码:
A
摘要:
目的　分析粪便 S100A12，钙卫蛋白（ fecal calprotectin ，FC）和乳铁蛋白（ lactoferrin ，LF）对溃疡性结肠炎（ulcerative colitis，UC）患者疾病活动度和黏膜愈合情况的评估价值。方法　选取 2018年 9月～ 2020年 7月期间营口市中心医院收治的 UC患者 125例，根据疾病活动度将其分为缓解组（ 72例）和活动组（ 53例），缓解组再根据黏膜情况分为黏膜愈合组（ 34例）和黏膜病变组（ 38例）。检测所有患者的粪便 S100A12，FC和 LF水平，采用 Pearson法分析粪便 S100A12，FC，LF与 UC镜下严重程度指数（ UCEIS评分）的相关性，采用受试者操作特征曲线（ROC）分析粪便 S100A12，FC和 LF对 UC患者疾病活动度和黏膜愈合的评估价值。结果　活动组的粪便 S100A12（1.21±0.36μg/g）， FC（326.38±153.54μg/g）和 LF（288.62±164.84μg/g）水平均明显高于缓解组（ 0.75±0.24μg/g, 138.52±63.28μg/g, 103.25±45.63μg/g），差异有统计学意义（ t=8.566～ 9.367，均 P<0.05）；黏膜病变组的粪便 S100A12（0.99±0.29μg/g），FC（188.94±70.94μg/g）和 LF（142.31±63.21μg/g）水平明显高于黏膜愈合组（0.48±0.21μg/ g，82.17±33.61μg/g，59.56±20.52μg/g），差异均有统计学意义（ t=7.295～ 8.458，均 P<0.05）。经 Pearson分析显示， UC患者的粪便 S100A12，FC，LF水平与 UCEIS评分均呈正相关（ r=0.426，0.438，0.417，均 P<0.05）；ROC分析显示，粪便 S100A12，FC，LF对 UC患者疾病活动度和黏膜愈合有一定的评估价值，且三者联合应用可有效提升评估价值，评估疾病活动度的曲线下面积为 0.895，敏感度和特异度分别为 88.70%和 90.28%，评估黏膜愈合的曲线下面积为 0.890，敏感度和特异度分别为 91.18%和 86.84%。结论　粪便 S100A12，FC和 LF联合应用对 UC患者疾病活动度和黏膜愈合的评估价值较高，具有一定的临床应用价值。
Abstract:
Objective　To analyze the value of stool S100A12, fecal calprotectin (FC) and lactoferrin (LF) in the evaluation of disease activity and mucosal healing in patients with ulcerative colitis (UC).Methods　125 patients with UC admitted to Yingkou Central Hospital from September 2018 to July 2020 were selected, and they were divided into remission group (72 cases) and active group (53 cases) according to disease activity. The remission group was further divided into mucosal healing group (34 cases) and mucosal lesion group (38 cases) according to the mucosal condition. The levels of stool S100A12, FC and LF in all patients were detected. Pearson method was used to analyze the correlation between stool S100A12, FC, LF and UC microscopic severity index (UCEIS score). Receiver operating characteristic curve (ROC) was used to analyze the evaluation value of stool S100A12, FC and LF for disease activity and mucosal healing of patients with UC. Results　The levels of stool S100A12（1.21±0.36μg/g），FC（326.38±153.54μg/g）and LF（288.62±164.84μg/g） in the active group were significantly higher than those in the remission group（0.75±0.24μg/g,138.52±63.28μg/g,103.25±45.63μg/g）, the differences were statistically significant (t=8.566 ～ 9.367, all P<0.05). The levels of stool S100A12（0.99±0.29μg/g），FC （188.94±70.94μg/g） and LF（142.31±63.21μg/g）in the mucosal lesion group were significantly higher than those in the mucosal healing group（0.48±0.21μg/g，82.17±33.61μg/g，59.56±20.52μg/g）, and the difference were statistically significant (t=7.295 ～ 8.458, all P<0.05). Pearson analysis showed that the levels of stool S100A12, FC and LF in patients with UC were positively correlated with the UCEIS score (r=0.426,0.438，0.417, all P<0.05). ROC analysis showed that stool S100A12, FC and LF had certain evaluation value for disease activity and mucosal healing of patients with UC, and the combined application of the three could effectively improve the evaluation value, the area under the curve for assessing disease activity was 0.895, the sensitivity and specificity were 88.70% and 90.28%, respectively. The area under the curve for assessing mucosal healing was 0.890, and the sensitivity and specificity were 91.18% and 86.84%, respectively. Conclusion　Stool S100A12, FC and LF combined application of disease activity and mucosal healing in patients with UC have a high evaluation value, and it has a certain clinical application value.

参考文献/References:

[1] EISENSTEIN M. Ulcerative colitis: towards remission[J]. Nature, 2018, 563(7730):S33.
[2] 王寅璞, 屈亚威, 贾馥华, 等. 高分辨率显微内镜对 溃疡性结肠炎黏膜愈合的评估价值[J]. 中华消化内 镜杂志,2019,36(4):255-260. WANG Yinpu,QU Yawei,JIA Fuhua,et al. Evaluative value of high-resolution microendoscopy on mucosal healing in ulcerative colitis [J]. Chinese Journal of Digestive Endoscopy,2019,36(4):255-260.
[3] NA S Y, MOON W. Evolving therapeutic strategies in the inflammatory bowel disease[J]. The Korean Journal of Gastroenterology, 2018, 71(2): 61-68.
[4] 李慕然, 孙静, 刘艳迪. S100A12 在溃疡性结肠炎和 腹泻型肠易激综合征患者中的表达及其意义 [J]. 中 华消化杂志,2016,36 (3): 199-201. LI Muran,SUN Jing,LIU Yandi.Expression and significance of S100A12 in patients with ulcerative c o l i t i s and diarrhea predominant irritable bowel syndrome[J].Chinese Journal of Digestion,2016,36(3):199-201.
[5] CARLSEN K, RIIS L B, ELSBERG H, et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis[J]. Scandinavian Journal of Gastroenterology, 2018, 53(7): 825-830.
[6] DAI Cong, JIANG Min, SUN Mingjun. Fecal markers in the management of inflammatory bowel disease[J]. Postgraduate Medicine, 2018, 130(7): 597-606.
[7] 中华医学会消化病学分会炎症性肠病学组. 炎症性 肠病诊断与治疗的共识意见(2018 年·北京)[J]. 中国 实用内科杂志,2018,38(9):796-813. Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J].Chinese Journal of Practical Internal Medicine,2018,38(9):796-813.
[8] 周正宇, 高谦, 景丽玲, 等. 中性粒细胞与淋巴细胞 比值对初发溃疡性结肠炎鉴别诊断及其严重程度判 断的临床意义[J].现代检验医学杂志,2018,33(1):145- 147,150. ZHOU Zhengyu, GAO Qian, JING Liling ,et al. Clinical significance of the ratio of neutrophil to lymphocyte in the differential diagnosis of primary ulcerative colitis and the judgment of its severity [J]. Journal of Modern Laboratory Medicine,2018,33(1):145-147,150.
[9] 曾毅, 陈思, 吴正祥, 等. 初诊溃疡性结肠炎治疗 后第1 年内肠黏膜愈合危险因素分析[J]. 山东医 药,2019,59(15):75-77. ZENG Yi,CHEN Si,WU Zhengxiang,et al.Risk factors for intestinal mucosal healing in the first year after treatment of newly diagnosed ulcerative colitis[J]. Shandong Medical Journal,2019,59(15):75-77.
[10] 胡艺丽, 李媛媛, 杨勤. 溃疡性结肠炎黏膜愈 合相关生物标志物的研究进展[J]. 实用医学杂 志,2018,34(21):3644-3647. HU Yili,LI Yuanyuan,YANG Qin.Research progress of biomarkers related to mucosal healing in ulcerative colitis[J]. The Journal of Practical Medicine, 2018,34(21):3644-3647.
[11] MINE S, TAKESHIMA F, AKAZAWA Y, et al. Correlation of fecal markers with magnifying endoscopic stratification in patients with ulcerative colitis who are in clinical remission[J]. Digestion, 2018, 97(1): 82-89.
[12] 郑静, 张铁, 韩呈武. 粪便生物标志物在炎症性肠病诊疗中的应用进展[J]. 检验医学与临床, 2018, 15 (15):2342-2346. ZHENG Jing, ZHANG Tie, HAN Chengwu. Application progress of fecal biomarkers in the diagnosis and treatment of inflammatory bowel disease[J]. Laboratory Medicine and Clinic,2018,15(15):2342-2346.
[13] PLANELL N, MASAMUNT M C, LEAL R F, et al. Usefulness of transcriptional blood biomarkers as a non-invasive surrogate marker of mucosal healing and endoscopic response in ulcerative colitis[J]. Journal of Crohn’s & Colitis, 2017, 11(11): 1335-1346.
[14] WHITEHEAD S J, FORD C, GAMA R M, et al. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12[J].J Clin Pathol, 2017, 70(12):1049-1056.
[15] HEIDA A, KOBOLD A C M, WAGENMAKERS L, et al. Reference values of fecal calgranulin C(S100A12)in school aged children and adolescents[J]. Clinical Chemistry and Laboratory Medicine, 2017, 56(1): 126-131.
[16] 陈立亚, 袁柏思, 韦成, 等. 粪便钙卫蛋白对溃疡性 结肠炎镜下活动及严重程度的评估价值[J]. 医学研 究生学报,2018,31(3):294-299. CHEN Liya,YUAN Bosi,WEI Cheng,et al. The value of fecal calprotectin in predicting endoscopic activity and severity of ulcerative colitis [J]. Journal of Medical Postgraduates,2018,31(3):294-299.
[17] CHEW T S, MANSFIELD J C. Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review[J]. Frontline Gastroenterology, 2018, 9(1): 23-28.
[18] LANGHORST J, BOONE J, LAUCHE R, et al. Faecal lactoferrin, calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: post Hoc analysis of a prospective clinical trial[J]. Journal of Crohn’s & Colitis, 2016, 10(7): 786-794.
[19] PUOLANNE A M, KOLHO K L, ALFTHAN H, et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease[J]. Digestive Diseases and Sciences, 2017, 62(11): 3123-3130.

相似文献/References:

[1]王 飞,祝 靳,赵宝林.溃疡性结肠炎患者血清LncRNA Mirt2 和LncRNA IFNG-AS1 表达水平及与预后相关性研究[J].现代检验医学杂志,2023,38(03):114.[doi:10.3969/j.issn.1671-7414.2023.03.020]
　WANG Fei,ZHU Jin,ZHAO Bao-lin.Study on the Expression Levels of Serum LncRNA Mirt2 and LncRNA IFNGAS1 in Patients with Ulcerative Colitis and Their Correlation with Prognosis[J].Journal of Modern Laboratory Medicine,2023,38(03):114.[doi:10.3969/j.issn.1671-7414.2023.03.020]
[2]关李稳,刘真义,周真真,等.溃疡性结肠炎患者血清LncRNA TUG1 和miR-142-5p 表达与疾病活动度及预后的关系[J].现代检验医学杂志,2023,38(05):70.[doi:10.3969/j.issn.1671-7414.2023.05.013]
　GUAN Liwen,LIU Zhenyi,ZHOU Zhenzhen,et al.Relationship between Serum LncRNA TUG1 and miR-142-5p Expression and Disease Activity and Prognosis in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2023,38(03):70.[doi:10.3969/j.issn.1671-7414.2023.05.013]
[3]王 燕a,胡秀娟a,张 丽a,等.溃疡性结肠炎患者血清Elabela，LRG1水平表达与疾病活动指数的相关性研究[J].现代检验医学杂志,2024,39(01):100.[doi:10.3969/j.issn.1671-7414.2024.01.018]
　WANG Yana,HU Xiujuana,ZHANG Lia,et al.Correlation between the Expression of Serum Elabela, LRG1 Levels and Disease Activity Index in Patients with Ulcerative Colitis[J].Journal of Modern Laboratory Medicine,2024,39(03):100.[doi:10.3969/j.issn.1671-7414.2024.01.018]

备注/Memo

备注/Memo:
作者简介：杨思贤（1981-），女，硕士研究生，副主任医师，研究方向：消化系统相关疾病，E-mail：yangsixian897362@163.com。
更新日期/Last Update: 1900-01-01